Month: December 2024
-
Huawei wins Unified Patent Court injunction against Netgear over WiFi 6 in most important UPC SEP ruling to date
The Unified Patent Court’s Munich Local Division has granted Huawei a multi-country injunction against Netgear over a WiFi 6 standard-essential patent.
-
USITC judge sides with Ericsson on 4 out of 4 standard-essential patents, throws out Lenovo’s other defenses: U.S. import ban looms large
Lenovo has suffered a crushing preliminary defeat in the U.S. International Trade Commission as all four Ericsson standard-essential patents at the heart of the investigation have been held valid and infringed.
-
Swedish pharma giant Orexo settles Zubsolv patent dispute with Sun Pharmaceutical weeks before Federal Circuit appellate hearing
The Federal Circuit was due to hear Sun Pharmaceutical’s appeal against a District Court of New Jersey bench ruling finding it infringed Orexo’s Zubsolv patents on January 7, 2025.
-
Nokia’s Chinese licensing success story continues as wireless innovator announces patent license agreement with second Chinese car maker
Nokia has announced that a second unnamed automaker from China has taken a bilateral license to its cellular standard-essential patents.
-
Fractus files fresh IoT-related patent litigation, sues Geotab and Verizon in Eastern District of Texas
Lawsuits come after three successful patent licensing deals in the IoT market this year.
-
UPC Roundup (1 week): Munich LD allows subsequent assertion of another claim set; 9 seconds to revocation; CoA on injunction enforcement; and other developments
This is a summary of developments in the Unified Patent Court (UPC) since the previous roundup (December 7, 2024 ip fray article). There have been some interesting decisions lately, with quite a bit more to come before the holidays. 1. Assertion of additional category of patent claims during course of proceedings does not constitute an…
-
AstraZeneca defends record patent invalidation claims in China
The UK pharma giant has defeated 33 invalidation claims brought by Chinese generics manufacturers against crystal form patents related to its highest-selling diabetes drug.
-
Pfizer brought UPC revocation action 9 seconds after midnight on grant date, argues Glaxo jumped the gun with infringement filing
Pharmaceutical giants GlaxoSmithKline and Pfizer are embroiled in an interesting UPC venue fight that involves questions of timing.
-
China’s Supreme People’s Court settles mRNA patent, trade secrets litigation under President Xi’s new ‘Fengqiao’ dispute model
Chinese courts are imposing mediation on more and more cases under the new order, including those involving patent infringement.